Riding on its Covid-19 vaccine success, Moderna makes its first-ever acquisition


The Cambridge drugmaker (Nasdaq: MRNA) is using some of the billions of dollars it's been sitting on to acquire a Japanese DNA supplier in a $85 million deal.

Previous Sesen Bio defends its proposed merger with Carisma Therapeutics after investors voice opposition
Next Aetna to replace Blue Cross NC running multibillion-dollar State Health Plan